traded at ₹256.40 on NSE as of 11.49 AM on November 17, declining 1.97 per cent from the previous close of ₹261.55. The stock opened higher at ₹262.95 and touched an intraday high of ₹263.05 before slipping to a low of ₹254.15, with sell quantity exceeding buy quantity at 36,199 versus 21,776 shares.
The ethanol and bio-based chemicals manufacturer reported consolidated revenue of ₹434.3 crore for Q2 FY26, marking a 34 per cent year-on-year growth. However, the company posted a net loss of ₹41.6 crore, though significantly narrower than the ₹75 crore loss in the same quarter last year. EBITDA losses reduced to ₹4.4 crore from ₹31.5 crore, indicating early signs of recovery.
The bio-based chemicals segment delivered strong performance with 60 per cent EBITDA growth to ₹15 crore, while the ethanol segment turned profitable with ₹4.7 crore EBITDA against a loss of ₹2.9 crore in Q2 FY25. An exceptional expense of ₹26.7 crore was recognized for additional harvesting charges related to the 2023-24 sugar season.
The company’s anti-cancer research program received a boost with the successful completion of safety trials and a European patent grant. A 200 KLPD fungible grain distillery is targeted for commissioning in Q4 FY26. The stock has a market capitalization of ₹1,312 crore.